Status | Study |
Not yet recruiting |
Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Hepatosplenic T-Ce Date: 2017-03-01 Interventions: Other: Laboratory Biomarker Analysis |
Completed |
Study Name: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Hematological Mali Date: 2016-07-21 |
Recruiting |
Study Name: PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Condition: Acute Myelogenous Leukemia B-cell Acute Lymphoblastic Leukemia Date: 2016-03-31 Interventions: Biological: XmAb14045 Administered IV weekly up to 8 weeks |
Recruiting |
Study Name: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Condition: Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult T-Cell Leukemia/Lymphoma Date: 2016-01-08 Interventions: Other: Laboratory Biomarker Analysis |
Active, not recruiting |
Study Name: An Open-label Phase II Study of Lorvotuzumab Mertansine Condition: Leukemia Date: 2015-04-15 Interventions: Drug: Lorvotuzumab Mertansine (IMGN901) 100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle. |
Recruiting |
Study Name: Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Condition: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Acute Biphenotypic Leukemi Date: 2014-08-18 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Recruiting |
Study Name: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Condition: Adult Acute Myeloid Leukemia in Remission Donor Early Rela Date: 2014-06-06 Interventions: Drug: cyclophosphamide Given I |
Recruiting |
Study Name: SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Acute Myel Date: 2014-03-13 Interventions: Drug: SL-401 |
Withdrawn |
Study Name: Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas Condition: Stage III Ovarian Carcinoma Stage IV Ovarian Carcinoma Fal Date: 2014-01-07 Interventions: Biological: ovapuldencel-T Com |
Terminated |
Study Name: Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Condition: Stage IV Melanoma Stage III Melanoma Date: 2013-06-07 Interventions: Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) |